Furong Qiu

Furong Qiu

Auto-generated profile, based on publicly available information

Furong Qiu

Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Clinical Science
Verified
Journal Article
Open access
PDF file
GSGuochao Song
Guochao Song
FWFengyi Weng
Fengyi Weng
BZBin Zou
Bin Zou
JZJing Zhao
Jing Zhao
JJJingyi Jin
Jingyi Jin
FQFurong Qiu
Furong Qiu
Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employed to treat hepatobiliary disorders and is as effective as UDCA in alleviating cholestatic liver disease in clinical trials. Until now, TUDCA’s mechanism of action towards cholestasis remains unclear. In this study, cholestasis was induced with a cholic acid (CA)-supplemented diet or alpha-naphthyl isothiocyanate (ANIT) gavage in wild-type and Farnesoid X Receptor (FXR) deficient mice, using obeticholic acid (OCA) as control. The effects of TUDCA on liver histological changes, transaminase level, bile acid composition, hepatocyte death, expression of Fxr and Nuclear factor erythroid 2-related factor 2 (Nrf2) and target genes, as well as apoptotic signaling pathways, were investigated. Treating CA-fed mice with TUDCA markedly alleviated liver injury, attenuated bile acids retention in liver and plasma, increased Fxr and Nrf2 nuclear levels and modulated the expression of targets regulating synthesis and transportation of bile acids, including BSEP, MRP2, NTCP and CYP7A1. TUDCA, but not OCA, activated Nrf2 signaling and exerted protective effects against cholestatic liver injury in Fxr-/- mice fed with CA. Furthermore, in both mice with CA- and ANIT-induced cholestasis, TUDCA decreased expression of GRP78 and CCAAT/enhancer-binding protein homologous protein (CHOP); reduced Death Receptor 5 (DR5) transcription, caspase-8 activation, and BID cleavage; and subsequently inhibited activation of executioner caspases and apoptosis in liver. We confirmed that TUDCA protected against cholestatic liver injury by alleviating BAs burden of dually activating hepatic Fxr and Nrf2. Moreover, inhibiting CHOP-DR5-caspase-8 pathway contributed to the anti-apoptotic effect of TUDCA in cholestasis.

20 November 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BZBin Zou
Bin Zou
SZShuang Zhang
Shuang Zhang
JZJing Zhao
Jing Zhao
GSGuochao Song
Guochao Song
FWFengyi Weng
Fengyi Weng
FQFurong Qiu
Furong Qiu

22 August 2005 in Magnetic Resonance in Chemistry
Verified
Journal Article
Closed access
PDF file
FQFurong Qiu
Furong Qiu
SCShiming Chen
Shiming Chen
ZPZhenghua Ping
Zhenghua Ping
GYGongming Yin
Gongming Yin